The Scottish Medicines Consortium has accepted the following drugs for use within NHS Scotland:
- bendamustine hydrochloride (Levact) for chronic lymphocytic leukaemia when fludarabine not appropriate.
- sunitinib (Sutent) for unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in patients receiving best supportive care, including somatostatin analogues if required for symptomatic control.
- ticagrelor (Brilique) in combination with aspirin for the prevention of atherothrombotic events in acute coronary syndromes (including patients managed medically, with percutaneous coronary intervention or with CABG).
- sevalamer carbonate (Renvela) for hyperphosphataemia in patients on haemodialysis. Use is restricted to second-line treatment.
- iron isomaltoside 1000 (Monofer) for treatment of iron-deficiency anaemia with intolerance/resistance to oral iron or the need to deliver iron rapidly. Use is restricted to administration by high dose infusion and excludes patients receiving haemodialysis.
The SMC rejected botulinum toxin A (Botox) for use in migraine prophylaxis, calcium acetate and magnesium carbonate (Osvaren) and tocofersolan (Vedrop) following full submissions. Ethinylestradiol/drosperinone (Yasmin) and quetiapine prolonged release and immediate release (Seroquel XL and Seroquel) for the treatment of major depressive episodes in bipolar disorder were rejected following resubmissions.
Further information: The Scottish Medicines Consortium